Leihong Deng
Overview
Explore the profile of Leihong Deng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu F, Xu X, Deng H, Yu Z, Huang J, Deng L, et al.
Transl Oncol
. 2024 Aug;
49:102104.
PMID: 39197387
Background: The Ubiquitin-proteasome system (UPS) is known to participate in multiple cellular events. The deubiquitinating enzyme USP2 (ubiquitin-specific protease 2) is involved in the vasculature remodeling process associated with bladder...
2.
Lv Y, Liu Z, Deng L, Xia S, Mu Q, Xiao B, et al.
Sci Rep
. 2024 Jan;
14(1):1009.
PMID: 38200039
Patients with bladder cancer (BLCA) still show high recurrence after surgery and chemotherapy. Hesperetin (HE), as a natural compound, has attracted researchers' attention due to its low toxicity and easy...
3.
Deng H, Deng L, Chao H, Yu Z, Huang J, Song Z, et al.
Cell Death Discov
. 2023 Aug;
9(1):292.
PMID: 37558664
Bladder cancer (BLCA) is the 9th most common cancer of mortality. Autophagy and epithelial to mesenchymal transition (EMT) have an essential role in cancer invasion and metastasis. However, the relationship...
4.
Yu Z, Chao H, Xu F, Deng H, Deng L, Song Z, et al.
Front Oncol
. 2023 Apr;
13:1115718.
PMID: 37077837
Background: Biochemical recurrence (BCR) is common in prostate cancer (PCa), but its prediction is based predominantly on clinicopathological characteristics with low accuracy. We intend to identify a potential prognostic biomarker...
5.
Lv Y, Liu Z, Jia H, Xiu Y, Liu Z, Deng L
Exp Ther Med
. 2022 Oct;
24(5):676.
PMID: 36185766
Given its high recurrence and rapid progress, bladder cancer (BLCA) treatment has become a major problem for clinicians. BLCA is difficult to control even with surgical resection and extensive use...
6.
Gong Y, Lv Y, Xu F, Xiu Y, Lu Y, Liu Z, et al.
J Clin Lab Anal
. 2022 Sep;
36(9):e24648.
PMID: 36082464
Objective: The objective of the study was to investigate the expression of LAMTOR3 in kidney renal clear cell carcinoma (KIRC) and its clinical significance. Methods: The expression of LAMTOR3 in...
7.
Deng L, Chao H, Deng H, Yu Z, Zhao R, Huang L, et al.
BMC Cancer
. 2022 May;
22(1):510.
PMID: 35524222
Background: Better prognostic outcome is closely correlated with early detection of bladder cancer. Current non-invasive urianalysis relies on simultaneously testing multiple methylation markers to achieve relatively high accuracy. Therefore, we...
8.
Yu Z, Huang J, Deng H, Zeng Z, Deng L, Xu X, et al.
Cancer Manag Res
. 2021 Apr;
13:2909-2915.
PMID: 33833574
Purpose: To explore the application of the neobladder-urethral drag-and-bond anastomosis technique in laparoscopic radical cystectomy (LRC) with ileal orthotopic neobladder (IONB) reconstruction. Patients And Methods: This is a retrospective cohort...
9.
Deng L, Gu X, Zeng T, Xu F, Dong Z, Liu C, et al.
Oncol Lett
. 2019 Aug;
18(3):3236-3248.
PMID: 31452801
Docetaxel treatment is a standard chemotherapy strategy for castration-resistant prostate cancer (CRPC), and patients with CRPC eventually develop resistance to treatment. However, little is understood regarding the underlying mechanism of...
10.
Chao H, Deng L, Xu F, Fu B, Zhu Z, Dong Z, et al.
Carcinogenesis
. 2019 Jun;
40(9):1177.
PMID: 31194242
No abstract available.